| Date Filed | Type | Description |
| 08/12/2014 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 08/12/2014 |
SC 13D/A
| Baupost Group reports a 0% stake in Idenix Pharmaceuticals, Inc. |
| 08/12/2014 |
SC 13D/A
| NOVARTIS AG reports a 0% stake in Idenix Pharmaceuticals, Inc. |
| 08/12/2014 |
4
| NOVARTIS PHARMA AG (10% Owner) has filed a Form 4 on IDENIX PHARMACEUTICALS INC |
| 08/06/2014 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 08/05/2014 |
4
| WYZGA MICHAEL S (Director) has filed a Form 4 on IDENIX PHARMACEUTICALS INC |
| 08/05/2014 |
4
| Rowland Charles A Jr (Director) has filed a Form 4 on IDENIX PHARMACEUTICALS INC|
Txns:
| Disposed/sold 20,000 options to buy
@ $4.94, valued at
$98.8k
Disposed/sold 20,000 options to buy
@ $6.88, valued at
$137.6k
|
|
| 08/05/2014 |
4
| Pollard-Knight Denise (Director) has filed a Form 4 on IDENIX PHARMACEUTICALS INC |
| 08/05/2014 |
4
| HOWSON TAMAR D (Director) has filed a Form 4 on IDENIX PHARMACEUTICALS INC |
| 08/05/2014 |
4
| HODGSON THOMAS R (Director) has filed a Form 4 on IDENIX PHARMACEUTICALS INC|
Txns:
| Disposed/sold 20,000 options to buy
@ $18.88, valued at
$377.6k
Disposed/sold 20,000 options to buy
@ $8.85, valued at
$177k
Disposed/sold 20,000 options to buy
@ $7.33, valued at
$146.6k
Disposed/sold 20,000 options to buy
@ $6.71, valued at
$134.2k
Disposed/sold 20,000 options to buy
@ $3.49, valued at
$69.8k
Disposed/sold 20,000 options to buy
@ $4.09, valued at
$81.8k
Disposed/sold 20,000 options to buy
@ $4.57, valued at
$91.4k
Disposed/sold 20,000 options to buy
@ $9.03, valued at
$180.6k
Disposed/sold 20,000 options to buy
@ $4.94, valued at
$98.8k
Disposed/sold 20,000 options to buy
@ $6.88, valued at
$137.6k
|
|
| 08/05/2014 |
4
| HOCKMEYER WAYNE T (Director) has filed a Form 4 on IDENIX PHARMACEUTICALS INC |
| 08/05/2014 |
4
| Stahl Maria D (SVP & General Counsel) has filed a Form 4 on IDENIX PHARMACEUTICALS INC|
Txns:
| Disposed/sold 150,000 options to buy
@ $3.87, valued at
$580.5k
Disposed/sold 80,000 options to buy
@ $3.17, valued at
$253.6k
Disposed/sold 100,000 options to buy
@ $12.08, valued at
$1.2M
Disposed/sold 100,000 options to buy
@ $4.65, valued at
$465k
Disposed/sold 100,000 options to buy
@ $7.01, valued at
$701k
|
|
| 08/05/2014 |
4
| Renaud Ronald C JR (President & CEO) has filed a Form 4 on IDENIX PHARMACEUTICALS INC |
| 08/05/2014 |
4
| Mayers Douglas L (EVP and Chief Medical Officer) has filed a Form 4 on IDENIX PHARMACEUTICALS INC |
| 08/05/2014 |
4
| Fanning Paul (SVP, Human Resources) has filed a Form 4 on IDENIX PHARMACEUTICALS INC |
| 08/05/2014 |
4
| Dumas Jacques (EVP, Chief Scientific Officer) has filed a Form 4 on IDENIX PHARMACEUTICALS INC|
Txns:
| Disposed/sold 250,000 options to buy
@ $7.42, valued at
$1.9M
|
|
| 08/05/2014 |
4
| Beckman Daniella (SVP, CFO and Treasurer) has filed a Form 4 on IDENIX PHARMACEUTICALS INC |
| 08/05/2014 |
8-K
| Form 8-K - Current report |
| 07/31/2014 |
8-K
| Quarterly results|
Docs:
|
"IDENIX PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTH 2014 FINANCIAL RESULTS CAMBRIDGE, Mass., July 31, 2014 — Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter ended June 30, 2014. Second Quarter and Six Months 2014 Financial Results For the second quarter ended June 30, 2014, Idenix reported total revenues of $ million, compared to total revenues of $0.1 million in the second quarter of 2013. The Company reported a net loss of $64.5 million, or $0.43 per basic and diluted share, for the second quarter ended June 30, 2014, compared to a net loss of $28.9 million, or $0.22 per basic and diluted share, for the second qu..." |
|
| 07/31/2014 |
10-Q
| Quarterly Report for the period ended June 30, 2014 |
| 07/11/2014 |
4
| Renaud Ronald C JR (President & CEO) has filed a Form 4 on IDENIX PHARMACEUTICALS INC |
| 06/17/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/09/2014 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 06/06/2014 |
4
| WYZGA MICHAEL S (Director) has filed a Form 4 on IDENIX PHARMACEUTICALS INC |
| 06/06/2014 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 06/06/2014 |
4
| Rowland Charles A Jr (Director) has filed a Form 4 on IDENIX PHARMACEUTICALS INC|
Txns:
| Granted 20,000 options to buy
@ $6.88, valued at
$137.6k
|
|
| 06/06/2014 |
4
| Pollard-Knight Denise (Director) has filed a Form 4 on IDENIX PHARMACEUTICALS INC |
| 06/06/2014 |
4
| HOWSON TAMAR D (Director) has filed a Form 4 on IDENIX PHARMACEUTICALS INC |
| 06/06/2014 |
4
| HODGSON THOMAS R (Director) has filed a Form 4 on IDENIX PHARMACEUTICALS INC|
Txns:
| Granted 20,000 options to buy
@ $6.88, valued at
$137.6k
|
|
| 06/06/2014 |
4
| HOCKMEYER WAYNE T (Director) has filed a Form 4 on IDENIX PHARMACEUTICALS INC |
| 05/01/2014 |
8-K
| Quarterly results|
Docs:
|
"IDENIX PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS AND HCV PIPELINE REVIEW CAMBRIDGE, Mass., May 1, 2014 — Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter ended March 31, 2014. HCV Pipeline Review • In April 2014, Idenix reported positive seven-day proof-of-concept data from a phase I/II clinical trial for IDX21437, the Company's lead uridine-based nucleotide prodrug candidate. The trial demonstrated that IDX21437 was well tolerated and exhibited potent pan-genotypic activity with mean maximal viral load reductions of 4.2 - 4.3 log 10 IU/mL for treatment-naïve genotype 1, 2 and 3 HCV-infected patients ..." |
|
| 05/01/2014 |
10-Q
| Quarterly Report for the period ended March 31, 2014 |
| 04/29/2014 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/07/2014 |
8-K
| Other Events, Financial Statements and Exhibits |
|